Forrester TEI study shows SmartBear Swagger delivers 227% ROI, $1.1M value, seven-month payback, and faster API design, ...

Founded in 2018, LambdaTest rapidly became one of the most trusted names in cloud-based test orchestration and execution. They built a scalable, high-performance test cloud that removed flakiness, ...

APIs have silently become the glue that keeps everything together. Be it shipping a mobile app, orchestrating microservices, or running scalable test environments ...

Abstract: Large Language Models have emerged as the top-notch tool in the software engineering field, from requirement gathering and analysis to code generation. Several approaches have been developed ...

WASHINGTON — For the first time ever, American car companies will soon be required to test vehicle safety using dummies that are representative of women. Transportation Secretary Sean Duffy on ...

Christian has three years of experience writing in the gaming industry, including guides and reviews, for publications such as Dualshockers, Attack of the Fanboy, and PC Invasion. He has been an avid ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery)research ...

Elon Musk’s X, formerly known as Twitter, has introduced a new pay-per-use API model in an attempt to rebuild its once-thriving developer ecosystem. The platform, which previously charged flat monthly ...

Two years after revamping its developer programs and pricing, X is expanding the closed beta of a pay-per-use plan for its API to more developers. The social network is accepting applications from ...

X has announced a new pay-per-use self-serve API model in hopes of luring developers back to the platform. Credit: Gabby Jones/Bloomberg via Getty Images Good news! Elon Musk's X has heard the cries ...

Immune cells can target cancer in the clinic. The ability to test a gene-editing technology in mice on a large scale should improve such immunotherapies. Michael Hudecek is in the Department of ...